Wells Fargo Maintains Overweight on PROCEPT BioRobotics, Lowers Price Target to $34
Benzinga Newsdesk 8 months ago
NewsPrice TargetAnalyst Ratings
Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $51 to $34.
Wells Fargo analyst Nathan Treybeck maintains PROCEPT BioRobotics (NASDAQ:PRCT) with a Overweight and lowers the price target from $51 to $34.